News|Articles|January 12, 2026

GLP-1 Associated With Colorectal Cancer Prevention, Research Finds

Author(s)Bridget Hoyt
Fact checked by: Ariana Pelosci
Listen
0:00 / 0:00

Key Takeaways

  • GLP-1RAs reduced CRC risk by 35.7% compared to aspirin, with greater reductions in high-risk patients and younger individuals.
  • GLP-1RAs showed a favorable safety profile, with lower rates of gastrointestinal bleeding and kidney injury than aspirin.
SHOW MORE

Study findings show more colorectal cancer risk reduction and safety with the use of a GLP-1RA versus Aspirin.

GLP-1 receptor agonists (GLP-1Ras) significantly outperformed Aspirin (acetylsalicylic acid) in reducing the risk of colorectal cancer, regardless of a patient’s weight or diabetes status, according to research presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

At a median six-year follow-up for GLP-1RA users and five years for aspirin users, the use of a GLP-1RA reduced the risk of CRC by 35.7% compared with aspirin use. In high-risk patients, the risk was reduced by 42.1%. High risk was defined as having a first-degree relative with CRC, those with known genetic predisposition, and those with known high-risk comorbidities including ulcerative colitis and Crohn’s disease.

In a presentation of the data, Dr. Colton Frisco Jones, a hematology oncology fellow at The University of Texas, San Antonio Mays Cancer Center, described the study as “the first real-world head-to-head comparison of the efficacy and safety of GLP1-RA versus Aspirin for the primary prevention of CRC.”

“The large population size of this study and the favorable safety profile of GLP-1s versus Aspirin could underscore a potential public health impact,” said Jones. “These findings warrant prospective validation.”

Younger patients (ages 18 to 44) saw a greater reduction in the risk of CRC at 41.7% compared with a 21% risk reduction in those ages 45 to 64 and a 27.1% risk reduction in those age 65 or older.

Benefit was seen regardless of diabetes or BMI statuses. Patients with diabetes had a 25.4% CRC risk reduction and those without diabetes had a 41.2% risk reduction when taking a GLP-1RA.

Between GLP-1RAs, the following incidence reductions relative to Aspirin use were observed:

  • Semaglutide, 36.9%
  • Tirzepatide, 28.9%
  • Liraglutide, 56.4%
  • Dulaglutide, 52.9%

Those with a BMI over 30 had a 38.9% CRC risk reduction with GLP-1RA use versus 56.2% in those with a BMI less than 29.

Safety Events in Patients Taking a GLP-1RA versus Aspirin

Patients taking Aspirin had a higher rate of gastrointestinal bleeding (2.1%) versus those taking a GLP-1RA. The same was true for gastric ulcers (0.55% versus 0.5%) and acute kidney injury (2.8% versus 1.15%).

Those taking a GLP-1RA had higher incidence of nausea and vomiting (10.5% versus 9.7%), diarrhea (6.8% versus 5.4%) and abdominal pain (19% versus 16.3%).

Patient Selection and Observation

The primary end point for this study was CRC incidence with a secondary end point of incidence of adverse events related to GLP1-RA and Aspirin use.

Patients 18 to 90 years old from Jan. 1, 2000 to Jan. 1, 2024, were included, with the exclusion of patients taking other non-steroidal aromatase inhibitors (NSAIDs) besides Aspirin as well as those taking any hypoglycemic medications aside from GLP1-RA. Additionally, those with CRC prior to the study window were excluded. After exclusions, 140,828 patients in each arm were matched to either cohort A, GLP-1RA users, or cohort B, aspirin users.

The average age at index event was 58 ±13.5 in cohort A and 58 ±13.7 in cohort B\. Most patients were White (67% in each cohort) and female (67% in each cohort).

Colton and co-authors used data from the TrinetX database, containing information on 150 million patients from 106 health organizations. Patients from cohort A were matched to patients in cohort B via propensity score matching. Clinically meaningful sensitivity and subgroup analyses were performed, and those with outcomes before the study window were excluded.

GLP-1RAs in CRC Risk Reduction

Colton noted that Aspirin has been investigated as a means of CRC prevention but due to its “modest efficacy” and increased risk of bleeding, its use is limited; further, GLP-1RAs have been shown to have anti-inflammatory and antineoplastic due to PI3K/AKT/mTOR pathway inhibition. For these reasons, Colton and co-authors set to explore the use of GLP-1RAs as primary prevention for CRC.

Reference

“Glucagon-like peptide-1 receptor agonist vs aspirin for primary prevention of colorectal cancer: evidence from a real-world head-to-head comparison,” by Dr. Colton Frisco Jones et al., J Clin Oncol.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.


Related to this article

mammogram
Long-term Kisqali data, a new targeted drug, blood tests and AI are among the topics to watch at the 2026 San Antonio Breast Cancer Symposium.
Image of Pancreas
Rasonque (daraxonrasib), the first approved drug to directly target RAS in pancreatic cancer, nearly doubled survival in a key trial. Two patients, a caregiver and the professionals who care for people like them explain what it means to live with the disease.